10 A variety of genetic studies, both twin and adoptive, have also established a genetic basis for schizophrenia
spectrum that includes both schizophrenia and SPD.15 Both family and adoptive studies provide evidence for a greater prevalence of schizophrenia-related personality disorders in relatives of schizophrenic subjects,16 but genetic loading for schizophrenia Inhibitors,research,lifescience,medical in families of schizotypal probands may be less robust because schizophrenia is not as common or consistent in schizotypal probands as in family SB431542 cost members of schizophrenic patients.3 Twin studies suggest that differential heritable factors may in fact be identified within the schizophrenia spectrum or SPD: one reflecting more psychotic-like symptoms and the other reflecting more deficit or negative symptoms.17,18 Anxiety is increased in relatives of patients with cluster C diagnosis, the “anxious cluster”19 including dependent personality, and continuity of social anxiety has been documented in twin and longitudinal studies.20 Inhibitors,research,lifescience,medical Complex
personality disorders like borderline and SPD may emerge from substrates for more than one dimension. We will review dimensions related to these and other specific personality disorders. Inhibitors,research,lifescience,medical Strategy for genetic studies of prototypic personality disorders A variety of complementary approaches to identifying endophenotypes in the personality disorders may provide convergent validity for the most promising endophenotypes. Many of these strategies follow directly from the criteria proposed by Gottesman and Gould21 and Leboyer et al.1 Heritability could be established most definitively in large samples of twins in an epidemiologically ascertained sample that could provide enough variance for the major dimensions Inhibitors,research,lifescience,medical of these personality disorders. Subjects would be evaluated for clinical phenotypic measures by diagnostic interview, self-report measures, and mental status evaluations that reflect specific dimensions of psychopathology. Laboratory measures including Inhibitors,research,lifescience,medical neuropsychological, psychophysiological, or laboratory behavioral tests could then be measured in this population to
define potentially heritable endophenotypes. A complementary approach is to identify such endophenotypes in the Carnitine palmitoyltransferase II personality disorder in question, such as BPD or SPD, and demonstrate a specific increase in these endophenotypes compared with normal control or psychiatric comparison groups. State independence or longitudinal stability could be established in longitudinal studies with repeated measures of the endophenotypic tests of interest. Finally, genetic studies of clinically identified samples could be used to determine whether the endophenotypic measure cosegregates with the illness or personality disorder in family members, and is also found in nonaffected family members at a higher rate than in the general population.